Advertisement
Advertisement
U.S. Markets close in 43 mins
Advertisement
Advertisement
Advertisement
Advertisement

Tempest Therapeutics, Inc. (TPST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6800-0.0100 (-0.59%)
As of 02:59PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6900
Open1.7000
Bid1.6100 x 800
Ask1.7000 x 1200
Day's Range1.5700 - 1.8100
52 Week Range1.5700 - 15.5000
Volume26,914
Avg. Volume28,836
Market Cap11.609M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.2900
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
  • GlobeNewswire

    Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Stephen R. Brady, chief executive officer of Tempest, will present at the H.C. Wainwright 24th Annual Global Investment Conference. The company presentation will be available for on-demand viewing Monday, September 12, 2022, at 7:00 a.m. E

  • GlobeNewswire

    Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update. “In the second quarter, we presented promising trial results from TPST-1120, our novel PPARα antagonist, at the ASCO Annual Meeting. This was the first present

  • GlobeNewswire

    Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

    President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy TargetsSOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., will participate in a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the 2022 William Blair Biotech

Advertisement
Advertisement